Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

David Griffith, n/a

Sr. Vice-President, Non-Clinical and Clinical Development
Qpex Biopharma

Disclosure(s): Qpex Biopharma: Employee

Poster(s):

216 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Beta-lactamase inhibitor Xeruborbactam Alone and in Combination Meropenem in Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
217 - A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of the Lipopeptide QPX9003 in Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
218 - A Phase 1 Study of the Single-Dose Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor Xeruborbactam Administered as the Isobutyryloxymethyl Oral Prodrug to Healthy Adult Subjects
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
614 - Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered as the Oral Prodrug in Combination with Ceftibuten
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
615 - Pharmacodynamics (PD) of the Beta-Lactamase Inhibitor Xeruborbactam When Administered in Combination with Meropenem
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET
616 - Pharmacodynamics (PD) of the lipopeptide QPX9003 Against Acinetobacter baumannii and Pseudomonas aeruginosa in the Neutropenic Mouse Thigh Infection Model
Thursday, October 20, 2022
12:15 PM – 1:30 PM US ET